ABSTRACT
Thyroid carcinoma is the most common endocrine malignancy worldwide, among which papillary thyroid carcinoma (PTC) accounts for nearly 90%. World Health Organization (WHO) define papillary microcarcinoma (PMC) as PTCs with maximum dimension ≤ 10 mm, irrespective of the presence or absence of aggressive malignant behavior such as vocal cord palsy, multicentricity, tumor subtype, invasiveness, risk group stratification, clinically evident lymph node metastasis and distant metastasis. With the advent of high-resolution ultrasonography and more of fine needle aspiration (FNA) of thyroid nodules, the incidence of PMC is increasing worldwide. It can be detected as incidental or latent. PMCs often do not cause any symptoms and patients are asymptomatic. Treatment options are active surveillance or surgery. Individualized treatment options should be offered to patients with PMC according to tumor biology and the clinical context and values of the patient.
